These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 37509501)

  • 1. Multiple Omics Analysis of the Role of RBM10 Gene Instability in Immune Regulation and Drug Sensitivity in Patients with Lung Adenocarcinoma (LUAD).
    Wu L; Liu Q; Ruan X; Luan X; Zhong Y; Liu J; Yan J; Li X
    Biomedicines; 2023 Jun; 11(7):. PubMed ID: 37509501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional role of RBM10 in lung adenocarcinoma proliferation.
    Sun X; Jia M; Sun W; Feng L; Gu C; Wu T
    Int J Oncol; 2019 Feb; 54(2):467-478. PubMed ID: 30483773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RBM10 Deficiency Is Associated With Increased Immune Activity in Lung Adenocarcinoma.
    Liu B; Wang Y; Wang H; Li Z; Yang L; Yan S; Yang X; Ma Y; Gao X; Guan Y; Yi X; Xia X; Li J; Wu N
    Front Oncol; 2021; 11():677826. PubMed ID: 34367963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective poly adenylation predicts the efficacy of immunotherapy in patients with lung adenocarcinoma by multiple omics research.
    Wu L; Zhong Y; Yu X; Wu D; Xu P; Lv L; Ruan X; Liu Q; Feng Y; Liu J; Li X
    Anticancer Drugs; 2022 Oct; 33(9):943-959. PubMed ID: 35946526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RNA-binding motif protein 10 represses tumor progression through the Wnt/β- catenin pathway in lung adenocarcinoma.
    Cao Y; Geng J; Wang X; Meng Q; Xu S; Lang Y; Zhou Y; Qi L; Wang Z; Wei Z; Yu Y; Jin S; Pan B
    Int J Biol Sci; 2022; 18(1):124-139. PubMed ID: 34975322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RNA binding motif protein 10 suppresses lung cancer progression by controlling alternative splicing of eukaryotic translation initiation factor 4H.
    Zhang S; Bao Y; Shen X; Pan Y; Sun Y; Xiao M; Chen K; Wei H; Zuo J; Saffen D; Zong WX; Sun Y; Wang Z; Wang Y
    EBioMedicine; 2020 Nov; 61():103067. PubMed ID: 33130397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of RBM10 mutations in the development, treatment, and prognosis of lung adenocarcinoma.
    Li Z; Xue Q; Xu J; Zhang P; Ding B
    Cell Cycle; 2020 Nov; 19(21):2918-2926. PubMed ID: 33064970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional analysis reveals that RBM10 mutations contribute to lung adenocarcinoma pathogenesis by deregulating splicing.
    Zhao J; Sun Y; Huang Y; Song F; Huang Z; Bao Y; Zuo J; Saffen D; Shao Z; Liu W; Wang Y
    Sci Rep; 2017 Jan; 7():40488. PubMed ID: 28091594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Down regulation of RBM10 promotes proliferation and metastasis via miR-224-5p/RBM10/p53 feedback loop in lung adenocarcinoma.
    Sun X; Jia D; Yu Y
    Heliyon; 2024 Aug; 10(15):e35001. PubMed ID: 39144991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A gene mutation in RNA-binding protein 10 is associated with lung adenocarcinoma progression and poor prognosis.
    Yin LL; Wen XM; Li M; Xu YM; Zhao XF; Li J; Wang XW
    Oncol Lett; 2018 Nov; 16(5):6283-6292. PubMed ID: 30405763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CircPRKCI regulates proliferation, migration and cycle of lung adenocarcinoma cells by targeting miR-219a-5p-regulated CAMK1D.
    Sui MH; Zhang WW; Geng DM; Sun DJ
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(4):1899-1909. PubMed ID: 33660800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RBM10 inhibits cell proliferation of lung adenocarcinoma via RAP1/AKT/CREB signalling pathway.
    Jin X; Di X; Wang R; Ma H; Tian C; Zhao M; Cong S; Liu J; Li R; Wang K
    J Cell Mol Med; 2019 Jun; 23(6):3897-3904. PubMed ID: 30955253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and Functional Characterization of Essential Genes Related to Gefitinib Sensitivity in Lung Adenocarcinoma.
    Wang R; Zhang L
    Curr Med Chem; 2024 Apr; ():. PubMed ID: 38584557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigation of
    Cao Y; Lan D; Ke X; Zheng W; Zeng J; Niu N; Fu C; Deng W; Jin S
    Heliyon; 2024 Jun; 10(11):e32287. PubMed ID: 38912481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RBM10 Loss Promotes EGFR-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition.
    Bao Y; Zhang S; Zhang X; Pan Y; Yan Y; Wang N; Ren Y; Zuo J; Zong WX; Wang Z; Wang Y
    Cancer Res; 2023 May; 83(9):1490-1502. PubMed ID: 36853175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased cell apoptosis in human lung adenocarcinoma and
    Ji Y; Xie S; Jiang L; Liu L; Li L; Luo L; Chen Y; Zhang J; Yu L; Zhang Y; Tang N; Liu B
    Oncol Lett; 2017 Oct; 14(4):4663-4669. PubMed ID: 29085465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EZH2 as a prognostic-related biomarker in lung adenocarcinoma correlating with cell cycle and immune infiltrates.
    Fan K; Zhang BH; Han D; Sun YC
    BMC Bioinformatics; 2023 Apr; 24(1):149. PubMed ID: 37069494
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Wu C; Dong B; Huang L; Liu Y; Ye G; Li S; Qi Y
    Front Oncol; 2021; 11():754290. PubMed ID: 34745988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of prognostic genes in the tumor microenvironment of lung adenocarcinoma.
    Xu ZY; Zhao M; Chen W; Li K; Qin F; Xiang WW; Sun Y; Wei J; Yuan LQ; Li SK; Lin SH
    PeerJ; 2020; 8():e9530. PubMed ID: 32775050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RBM10 recruits METTL3 to induce N6-methyladenosine-MALAT1-dependent modification, inhibiting the invasion and migration of NSCLC.
    Cao Y; Di X; Cong S; Tian C; Wang Y; Jin X; Zhao M; Zhou X; Li R; Wang K
    Life Sci; 2023 Feb; 315():121359. PubMed ID: 36608868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.